

Table of Contents

| | |
|---|----|
| 1. Objectives and Scope | 2 |
| 1.1. Map and Mitigate ESG Risks | 2 |
| 1.2. Ensure Progress on ESG and Impact Objectives | 2 |
| 1.3. Develop and Train Employees on Responsible Investment Key Issues | 2 |
| 1.4. Build Internal Capacity within the Investment Team | 2 |
| 2. Responsible Investment Approach | 3 |
| 2.1. IMPACT – Contribute to Health Objectives | 4 |
| 2.2. ESG – Build Responsible Businesses..... | 4 |
| 2.3. ENGAGEMENT – Align interests | 4 |
| 2.4. TRANSPARENCY – Monitoring and Reporting | 4 |
| 3. Governance | 5 |
| 3.1. Sustainability & Impact Team..... | 5 |
| 3.2. ESG Committee | 5 |
| 3.3. The Impact Referent..... | 6 |
| 3.4. Investment Committee | 6 |
| 3.5. Post-Investment: Deal Teams..... | 6 |
| 3.6. Remuneration | 6 |
| 3.7. Conflicts of Interest..... | 6 |
| 4. ESG & Impact Integration within our Investment Process | 7 |
| 5. Industry Engagement | 11 |
| 6. Investor Reporting & Regulatory Disclosures | 12 |
| 7. Glossary of Terms | 13 |

1. Objectives and Scope

By setting out our sustainability commitments and cross-referencing our practices with existing regulations and major impact frameworks, this policy aims to:

1.1. Map and Mitigate ESG Risks

Unintended harm to environmental, social and governance dimensions can have a detrimental impact on businesses, often in the form of costly fines, lawsuits, directors' personal liability and reputational damages. Proactively mapping and measuring these risks are therefore a critical step for developing robust controls and resilient businesses.

1.2. Ensure Progress on ESG and Impact Objectives

At ARCHIMED, we strive for continuous improvement of our responsible investment practices within our firm and across our portfolio. It is our mission to ensure we stay ahead of our sustainability commitments through the constant monitoring and adoption of international standards, updating of our existing procedures and applying our sustainability and impact expertise through our board representations.

1.3. Develop and Train Employees on Responsible Investment Key Issues

At ARCHIMED, we believe that involving our entire team in our responsible investment strategy is a key driver of its successful implementation. To that end, strengthening ESG related knowledge and skills across teams is a key priority. Alongside this policy, the S&I Team seeks to continuously develop digital resources via MED Learning Hub to facilitate knowledge sharing and training.

1.4. Build Internal Capacity within the Investment Team

Equipping our investment teams with policies and procedures is critical to ensuring the proper evaluation of investment targets, the sustainability performance of portfolio companies, and accelerate positive impacts on health. To further strengthen this learning path, the S&I Team seeks to conduct regular training on sustainability, as well as organizing formal, focused sessions on the internal sustainability tool and impact assessment processes.

This Policy applies to all ARCHIMED staff, including both Strategic and Operating Partners, as well as our portfolio companies across our Funds. It covers all non-listed assets, representing more than 95% of global assets under management:

| Fund Name | SFDR Classification |
|-----------------|---------------------|
| MED I | Article 8 |
| MED II | Article 8 |
| MED III | Article 8+ |
| MED Platform I | Article 8 |
| MED Platform II | Article 9 |
| MED Rise | Article 8+ |
| MED Access | Article 8 |

Last update: February 2025

2. Responsible Investment Approach

At ARCHIMED, we see human, animal and environmental health as a common value and a key condition to long-term sustainable development. Our goal is to make tangible healthcare advancements; by enhancing the resiliency of our portfolio companies, we are supporting the provision of sustainable and life changing healthcare solutions and fulfilling our stewardship role. This ethos encapsulates ARCHIMED's DNA; only through the rigorous application of our responsible investment strategy are we able to accelerate the delivery of equitable healthcare systems and facilitate global access to healthier lifestyles.

The ARCHIMED team brings decades of medical, scientific, operational, and financial experience, all of which is leveraged to focus on accelerating the growth of healthcare companies through innovation, internationalization, acquisitions, and capacity expansions. Thanks to the team's unique healthcare expertise, ARCHIMED has consistently delivered excellent performance to investors in terms of financial returns, sustainability improvements and positive health impacts; these outcomes serve as the underlying drivers behind the ARCHIMED **responsible investment approach**:

- VISION – human, animal, and environmental health is a common value amongst all people and a key condition for long-term development.
- MISSION – to join forces with scientists, healthcare professionals, entrepreneurs, and investors to drive the sustainable development of the healthcare industry through ARCHIMED's three main activities:
 - 1) FUND – to ensure Funds are channeled into companies contributing to improving healthcare outcomes, while achieving sustainability and impact objectives.
 - 2) SUPPORT - to empower healthcare entrepreneurs in their companies' development, seeking to drive value for multiple stakeholders and build a better healthcare future.
 - 3) RETURN - to deliver superior returns to investors and fair rewards to portfolio companies, but also to have a wider impact on society by supporting charitable projects through the EURÊKA Foundation.
- AMBITION – by driving more resources to the healthcare industry, ARCHIMED is improving people's health and economic status across all levels.

To further ingrain the ARCHIMED responsible investment approach and make it synonymous with our overall investment strategy, we made four **sustainability commitments** that outline the mechanisms for its implementation:

2.1. IMPACT – Contribute to Health Objectives

- Pre-investment: Assessment of contribution to Health Objectives and SDG targets ('impact potential assessment')
- Defining a clear Impact Thesis for investments contributing to the sustainable objective of the Fund
- Setting short and long term ESG and impact targets within the Sustainability Roadmap and monitoring progress against these targets through specific KPIs
- Accelerating our impact on health through the Five Dimensions of Impact framework

2.2. ESG – Build Responsible Businesses

- Pre and post investment: Assessment of ESG materiality and maturity
- Establishment of Sustainability Roadmap with specific milestones that are reviewed yearly
- Regular discussions on key ESG topics at board level and continuous engagement with companies to ensure sustainability stewardship


2.3. ENGAGEMENT – Align interests

- Integration of impact and ESG topics at company board level
- Top management variable remuneration aligned with progress on the Roadmap
- ARCHIMED investment team variable remuneration aligned with sustainability objectives

2.4. TRANSPARENCY – Monitoring and Reporting

- Regular assessment of progress against the Roadmap
- Integration of the Principle Adverse Indicators (PAIs) within due diligence
- Annual data collection to measure, monitor and report on ESG performance publicly via ARCHIMED's yearly Sustainability and Impact Reports, as well as within Quarterly investor reports

Every ARCHIMED Fund was created with the objective of directing investments towards companies whose ultimate goal is to improve health outcomes, and we assist all portfolio companies on developing and acting upon their CSR and ESG strategies. Our more recent Funds, namely MED III, MED Platform II and MED Rise, have an additional aspect of their mandate relating to impact. These Funds target investments that seek to generate a positive and measurable social impact, at either the human, animal, or environmental health level. This is determined through assessing each investments potential contribution to one of more targets of SDG 3: 'Good Health and Wellbeing' and SDG 9: 'Industry, Innovation and Infrastructure', utilizing ARCHIMED's five Health Objectives (depicted below) as a framework from which this is analyzed:



We define:

- SAFETY as the avoidance of unintended harm during the provision of healthcare
- EFFICACY as the ability of a product or treatment to provide a beneficial effect
- ACCESSIBILITY as the ease with which products and health services are reachable to all
- AFFORDABILITY as the degree to which a product or service is obtainable based on price
- EFFICIENCY as the ability to manufacture a product or deliver a service at a lower cost and faster delivery

3. Governance

3.1. Sustainability & Impact Team

The S&I team at ARCHIMED is responsible for the implementation of ARCHIMED’s responsible investment strategy and the wider sustainability and CSR strategy at ARCHIMED. Leveraging on their tailored expertise and interdisciplinary skillsets, the S&I team work collaboratively across the company, supporting multiple ARCHIMED teams to realize sustainability value creation; be it during the investment cycle or embedded within our reporting and communication activities.

3.2. ESG Committee

The ESG Committee oversees ARCHIMED and portfolio level sustainability. It comprises members of the Management Committee and the Director of S&I. The ESG Committee meets on an ad-hoc basis to discuss sustainability updates in general and serves as an opportunity to bring up deals in which the impact potential is more complex to assess. When relevant, Operating or Strategic Partners, externals with specific expertise in the ESG or impact may also attend. The Compliance team may also be involved as required. The ESG Committee reports to the Management Committee who holds ultimate responsibility for the ESG and Impact strategy.

3.3. The Impact Referent

The role of Impact Referent was created with a view to building internal capacity and further embedding a sustainability and impact mindset within the ARCHIMED teams. The appointed individuals should seek to collaborate, support, generate and disseminate knowledge and ensure the target investment fits ARCHIMED's Funds' mandates. The 'Impact Referent' is a member of the investment deal team who is appointed to ensure all ESG and Impact workstreams are completed in accordance with this policy and in a timely manner, with the support of the S&I team.

3.4. Investment Committee

The Investment Committee comprises Investment Partners and is the ultimate responsible for approving new investments.

3.5. Post-Investment: Deal Teams

Post-investment, the deal team members are in charge of proactively engaging with portfolio company management to ensure the key actions of the companies' individual Sustainability Roadmaps are completed according to the pre-defined timeline. ARCHIMED systematically takes board seats with portfolio companies and is therefore able to directly monitor impact and ESG performance.

3.6. Remuneration

ARCHIMED has implemented a Remuneration Policy that details the process in place relating to compensation. In addition, all team members, including Partners, have sustainability objectives linked to the implementation of our responsible investment strategy within our investment approach. To fully align business interests with sustainability and impact objectives, ARCHIMED has mandated that 20% of the CEO's variable remuneration is linked to the achievement of the Roadmap for MED III, MED Platform II and MED Rise investments.

3.7. Conflicts of Interest

Conflicts of interest are managed in accordance with our Ethics Charter and each individual employment agreement.

4. ESG & Impact Integration within our Investment Process

ARCHIMED's responsible investment strategy is embedded within every stage of the investment cycle and has been applied across all Funds since 2021. Keeping our approach dynamic and subjecting it to constant scrutiny has resulted in a refined, proprietary framework that enables us to identify the companies that not only contribute to positive health outcomes today, but ones that we can work with to building leading responsible businesses designed to leave a positive footprint on society beyond ARCHIMED's investment horizon.

From the outset, we engage with the portfolio companies to ensure they are upholding the highest ESG standards and advise them on their Corporate Social Responsibility ('CSR') strategies by working with them to develop Sustainability Roadmaps that state their impact and ESG objectives and detail actionable targets against which to monitor progress. By channeling investment towards sectors, companies, entrepreneurs and teams that deliver better health outcomes, we directly contribute to the positive social sustainable investment objectives of ARCHIMED's latest Funds: MED III, MED Platform II, and MED Rise.

PRE-INVESTMENT

- Prior to the first investment committee (PIC 1) an **Impact Referent** is appointed from the deal team. It is their responsibility to complete ARCHIMED's proprietary **Internal Sustainability Tool (IST)** which was developed to carry out a preliminary ESG and impact assessment. The appointed **Reviewer** assesses and challenges the **Impact Thesis** developed by the deal team in collaboration with the S&I team. In specific situations, an **Impact Reviewer** may be appointed.
 - 1) An initial **negative screening** is conducted based on ARCHIMED's **exclusion and watchlist criteria**. Subjecting potential investments to a high degree of scrutiny enables us to filter activities that raise critical ethical risks associated with investing in healthcare, such as bioethics issues, risks of substance dependence, or aggressive marketing tactics.
 - 2) This is followed by a **positive screening** analysis, or impact potential assessment, and serves to identify the **intentionality, additionality, and measurability** aspects through the **five dimensions of impact** to determine the investment's contribution to the relevant **SDG targets**, and subsequently to determine contribution to at least one of ARCHIMED's **Health Objectives**.
 - 3) The third part of the tool includes a high-level **ESG assessment** which is performed to determine the materiality of different ESG risks and the investee company's related maturity on these topics. This process serves to highlight which areas should be prioritized during later due diligence, and also provides a starting point for ESG discussions with management.
 - 4) All elements of the Internal Sustainability Tool are systematically reviewed and challenged by the S&I team. Once validated, the results of the screening

analyses and ESG assessment are used to develop the Impact Thesis which is subsequently included within the PIC1 memo and discussed during each meeting.

DUE DILIGENCE

- If the deal progresses past PIC2, **full ESG & Impact due diligence** is carried out with external consultants. The scope of the full ESG & Impact DD systematically includes climate risk and biodiversity risk assessments.
- If deemed necessary, **topic-specific due diligence** may be performed (e.g. on impact, animal health, supply chain or environmental factors) before or after PIC2, depending on the nature of the investment at hand and results of the IST.
- The results of the due diligence are presented in the investment committee papers. If any red flags are brought to light during either phase of the due diligence, it is determined whether the risks posed can be minimized or reduced entirely via the implementation of tailored mitigation action post-closing. If so, these actions are included in the **post-completion action plan ('PCAP')** as required, for example the need to conduct a carbon footprint assessment post-closing. If the risk is deemed irreversible during the holding period, the deal will not be progressed with.

POST-INVESTMENT / HOLDING PERIOD

- The PCAP for all investments requires an in-depth **Sustainability Assessment** to be conducted either by the ARCHIMED S&I team or by external consultants within the first year of closing, the outcome of which is a company-specific **Sustainability Roadmap**. ARCHIMED's **S&I team** provides extensive support during the first year of investment and onboards the post-investment **Impact Referent** to ensure the mission is carried out through the holding period. ARCHIMED teams support the portfolio companies through this process and facilitate the Roadmap development and implementation once finalized.
- Within the scope of this workstream, the Impact Thesis and key insights on the company's ESG maturity and materiality are investigated. Based on this, objectives and targets are set within the Roadmap that are inclusive of improvement actions and KPIs to monitor performance.
- Sustainability topics are systematically addressed at board level (frequency to be adapted to the specific situation of the portfolio company, with a recommended quarterly review, duly documented in board packs), on which ARCHIMED takes multiple seats, and are acted upon by portfolio companies with the continuous support and engagement from both the ARCHIMED S&I team and deal teams.
- As part of the **annual ARCHIMED ESG reporting campaign**, ESG and impact data is collected from each portfolio company. Routine **follow-up interviews** are carried out to assess company progress against Roadmap targets, and to reprioritize where necessary.
- After being validated and analyzed, key ESG and impact metrics at the individual company level as well as aggregated across the Fund and entire portfolio levels, and are shared across our various reporting methods:
 - Quarterly LP reporting

- Annual Sustainability and Impact Report
- Regulatory disclosures e.g. SFDR, CSRD, LEC29
- Our **ESG Essentials**, a set of impact and ESG indicators and objectives based on the UN SDGs, enable us to guide our companies in making concrete progress across material sustainability topics. While the **impact indicators and objectives** are specific to each portfolio company, the **ESG indicators and objectives**, based on SDGs 9, 12, 5, 13 and 16, are common to all portfolio companies. For most indicators, ARCHIMED has established an implementation objective of 100% of portfolio companies. An objective of 70% has been defined for indicators that can be more complex or challenging to implement. In these cases, the aim is to incrementally increase the percentage or coverage on an annual basis.

| SDG | COMMITMENT | INDICATOR | OBJECTIVE |
|---|---|---|---|
|  <p>9 INDUSTRY, INNOVATION AND INFRASTRUCTURE</p> | Significantly raise the healthcare industries' share of employment and gross domestic product, in line with national circumstances | Net job creation | Increase during ownership and at exit across all funds [70% of portfolio companies] |
| | Enhance scientific research, upgrade the technological capabilities of industrial sectors in all countries, encouraging innovation and substantially increasing the number of R&D workers | Company's valuation in its home country | Increase at exit across all funds [100% of portfolio companies] |
| | | Capacity/industrial capex | Increase across all funds for industrial companies |
| | | R&D/innovation spend/capex | Increase across all funds for innovation-focused companies |
|  <p>12 RESPONSIBLE CONSUMPTION AND PRODUCTION</p> | Improve ESG practices | Has the company clearly set its ESG objectives for the year? | 100% of portfolio companies across all funds |
| | Reduce resource consumption or waste production | Has the company clearly set its governance of ESG topics? | 100% of portfolio companies across all funds |
| | | Has the company implemented eco-design initiatives on a product/service? | 70% of portfolio companies across all funds |
| | Mitigate risks of negative environmental or social externalities across the healthcare supply chain | Has the company implemented a Responsible Procurement Policy with clear environmental and social criteria? | 70% of portfolio companies across all funds |
| | | Does the company collect ESG indicators from its main suppliers? | 70% of portfolio companies across all funds |
| | Ensure alignment of interests | Is the variable remuneration of top management linked to the achievement of ESG objectives? | 100% of portfolio companies across all funds (when CEO has variable remuneration scheme in place) |
| Is the variable remuneration of deal teams linked to the achievement of ESG objectives of their portfolio companies? | | 100% of portfolio companies across all funds | |
|  <p>5 GENDER EQUALITY</p> | Foster and ensure gender equality in our companies (pay, promotion, career development) | Is the company assessing if women are paid at the same level as men for the same roles? | 100% of portfolio companies across all funds |
| | Has the company implemented clear initiatives/programs to close any possible gap in salary and/or career development potential? | 100% of portfolio companies across all funds | |
|  <p>13 CLIMATE ACTION</p> | Limit impact on biodiversity and climate change and ensure resilience of our portfolio | Has a mapping of the physical and transitional risks of climate change and biodiversity loss been conducted on the company? | 70% of portfolio companies across all funds |
| | Reduce carbon footprint | Has the company set decarbonization targets, based on a carbon footprint assessment aligned with the Greenhouse Gas (GHG) Protocol and validated by external experts? | 90% of portfolio companies across all funds |
| | | % decrease in GHG emissions (in intensity) | Demonstrate decrease in intensity across the portfolio company, fund and portfolio levels |
|  <p>16 PEACE, JUSTICE AND STRONG INSTITUTIONS</p> | Ensure robust governance mechanisms are in place | Does the company have a formalized code of ethics in place? | 100% of portfolio companies across all funds |
| | | Does the company have a data privacy policy? | 100% of portfolio companies across all funds |

EXIT

- During the exit process, ARCHIMED may engage a specialist consultant to complete an **ESG Vendor Due Diligence** ('ESG VDD') report to demonstrate the ESG and impact performance of the portfolio company during the holding period to future investors, and its adherence to the Sustainability Roadmap which ultimately led to realized **value creation**. The ESG VDD report typically includes environmental, social, and governance related disclosures, key KPIs, alignment to material SDGs and to ARCHIMED's Health Objectives.
- the **Impact Referent** is responsible for maintaining ESG-related documents (and making them available upon request), which typically include:
 - Sustainability Assessment and Roadmap
 - Company specific ESG scorecards
 - Relevant policy documents the company has developed over the holding period, e.g. climate policies or carbon footprint assessments and any certifications or memberships they have gained, such as B-Corp or EcoVadis

5. Industry Engagement

Demonstrating ARCHIMED's long-standing commitment to integrating sustainability best practice within our investment approach, we are involved with the following industry initiatives:

- **The United Nation's Principles of Responsible Investment** ('PRI') is the leading international network of financial institutions working to implement its six principles offering possible actions for incorporating ESG issues into investment practice. In 2018, ARCHIMED became a signatory of the PRI, demonstrating our long-standing commitment to integrating ESG criteria into our investment strategy.
- **The initiative Climat International** ('iCI') is a collective call to action for private equity firms recognizing the industry's role in tackling climate change and reducing its carbon emissions. In 2020, we became a signatory of iCI, and are working towards building a climate-resilient portfolio and measuring our carbon footprint to develop a climate strategy aligned with the Paris Agreement.
- Since 2022, we have been an active member of the **France Invest Sustainability Commission GT1**, supporting the mission of this working group to promote ESG within the investment realm and develop action plans on priority themes such as climate change and biodiversity.
- **The European Data Convergence Initiative** ('EDCI') aims at driving convergence around a standardized set of ESG metrics alongside a mechanism for comparative reporting to benefit all stakeholders in the private markets, which ARCHIMED joined in January 2025.

6. Investor Reporting & Regulatory Disclosures

All sustainability-related regulatory disclosures can be found in the dedicated '[SFDR Disclosures](#)' area of ARCHIMED's website, which includes the following:

- EU SFDR Article 5 Remuneration Policy
- EU SFDR Article 8 and 9 Period Disclosure Annexes IV and V
- EU SFDR Article 8 and 9 Summary of Sustainability Disclosure documents
- Statement on the Principle Adverse Impacts (PAIs)
- Annual PAI Reports
- Annual Loi Energie et Climat (LEC) Article 29 Rapports

The EU SFDR Article 8 and 9 Pre-Contractual Disclosure Annexes II and III have been made available on our investor data platform.

Investors are kept abreast of relevant information in the "Sustainability News" section of ARCHIMED's quarterly LP reports, and specific sustainability updates are regularly provided for ad-hoc investor requests.

In addition, ARCHIMED's S&I team produces a group-level Sustainability and Impact Report on an annual basis. These are made publicly available in the '[Publications](#)' section of ARCHIMED's Sustainability & Impact page of the website.

To ensure that we follow the highest industry standards, our responsible investment strategy has been built upon a range of established international sustainability and impact frameworks, including but not limited to:

- The Sustainability Accounting Standards Board ('SASB')
- United Nations' Sustainable Development Goals ('SDGs')
- United Nations' Principles of Responsible Investment ('PRI')
- The Five Dimensions of Impact
- The World Health Organization ('WHO')
- The EU Sustainable Financial Disclosure Regulation ('EU SFDR')
- The EU Corporate Sustainability Reporting Directive (CSRD)
- Article 29 of the Energy-Climate Law ('LEC29')
- ARCHIMED's own health statements

7. Glossary of Terms

| | |
|---|--|
| <p>Sustainability Risk</p> | <p>A sustainability risk is an environmental, social or governance-related event or situation which, should it occur, could have a significant or potential adverse impact on the value of the investment.</p> <p>Sustainability factors include environmental, social and personnel issues, respect for human rights and the fight against corruption and acts of corruption.</p> <p>In their sustainability risk policy, made public pursuant to Article 3 of the Regulation of the European Parliament and of the Council concerning the publication of information on sustainable investments and sustainability risks, amending Directive (EU) 2016/2341, French investment management companies include information on the risks related to climate change as well as on the risks associated with biodiversity.</p> |
| <p>Climate Change Physical Risk</p> | <p>Risks associated with meteorological and weather-related phenomena, such as:</p> <ul style="list-style-type: none"> - loss of value of investments held by Funds managed and issued by entities affected by these weather events; - the increase in the frequency and cost of claims payable by insurers to policyholders; <p>Climate change or the loss of biodiversity are integrated in this risk.</p> |
| <p>Climate Change Transition Risks</p> | <p>Risks associated with the adjustments required in view of a transition: exposure to changes triggered by the ecological transition, in particular the environmental objectives defined by the Taxonomy regulation¹, in particular when they are poorly anticipated or occur suddenly. These risks are linked, for example, to:</p> <ul style="list-style-type: none"> - the depreciation of assets, following regulatory changes that would adversely impact, or even prohibit, certain activities that are deemed to emit too many greenhouse gases (GHGs); - losses following the end of certain Funded activities deemed to be too polluting or emitting too many GHGs |
| <p>Social Risk</p> | <p>Social risk concerns the review of the company's relationship with its stakeholders: employees, customers, suppliers, civil society. It includes, in particular, the protection of employees with respect to health and safety, the fight against discrimination, their well-being, respect for human rights within the supply chain or the company's philanthropic approach, its relations with local communities, customer satisfaction, etc.</p> |
| <p>Governance Risk</p> | <p>Governance risk encompasses both the competence of the company's management team, the structure of the CEO compensation plan or its legitimacy, and the existence of checks and balances. The assessment of this last point entails analyzing the composition of the boards of directors, the suitability of the professional backgrounds of directors with the needs of the company, their independence, respect for minority shareholders, business ethics and the company's commitment to CSR issues.</p> |

¹ The environmental objectives of the **Taxonomy Regulation** are: climate change mitigation, climate change adaptation, sustainable use and protection of aquatic and marine resources, transition to a circular economy, prevention and reduction of pollution, protection and restoration of biodiversity and ecosystems

| | |
|---|--|
| Principal Adverse Impacts (PAIs) | The effects of investment decisions that have adverse effects, whether significant or likely to be significant, on sustainability factors (environmental, social and personnel governance). |
| Sustainable Investments | Means an investment in an economic activity that contributes to an environmental or social objective, provided that the investment does not significantly harm any environmental or social objective and that the investee companies follow good governance practices. |
| CSR | <p>Corporate social responsibility (CSR) or corporate social impact is a form of international private business self-regulation which aims to contribute to societal goals of a philanthropic, activist, or charitable nature by engaging in, with, or supporting professional service volunteering through pro bono programs, community development, administering monetary grants to non-profit organizations for the public benefit, or to conduct ethically oriented business and investment practices.</p> <p>CSR strategies encourage the company to make a positive impact on the environment and stakeholders including consumers, employees, investors, communities, and others.</p> |
| The Five Dimensions of Impact | The Five Dimensions of Impact (What, Who, How Much, Contribution and Risk) is a set of norms assessing the impacts of enterprises on people and the planet. More information can be found at: https://impactfrontiers.org/norms/five-dimensions-of-impact/ |
| SDG Targets | The targets related to each Sustainable Development Goal. More information can be found at: https://sdgs.un.org/goals |
| Biodiversity | Biodiversity represents the entire living fabric of our planet, encompassing genetic diversity, species diversity, and the interactions that exist between ecosystems, species and individuals. Among numerous studies and reports, a key reference framework has recently emerged through the work of the TNFD (Taskforce on Nature-related Financial Disclosures) . The TNFD proposes a reference analysis framework dedicated to nature-related risks and opportunities, as well as recommendations relating to assessment and reporting processes for companies and financial institutions. |
| Nature-related risks | The TNFD defines nature-related risks as “the potential threats posed to an organization linked to its and other organizations’ dependencies on nature and nature impacts. These can derive from physical, transition and systemic risks.” |
| Biodiversity Physical Risks | Physical risks are the direct result of an organization’s dependencies on nature. These nature-related physical risks result from changes in the biotic (living) and abiotic (non-living) conditions that allow ecosystems to function properly. They occur when natural systems are compromised, due to the impact of climatic events (e.g. extreme weather conditions such as drought), geological events (e.g. earthquake) or changes in the balance of ecosystems (e.g. changes in soil quality or ocean chemistry). |
| Biodiversity Transition Risks | Transition risks are risks that result from a misalignment between an organization’s strategy and management and the changing context in which it operates, particularly with regard to developments aimed at stopping or reversing damage to nature. Regulations or government policies, technological developments, market developments including changes in consumer preferences, as well as disputes and controversies can give rise to these transition risks. |

ARCHIMED

IMPACTING HEALTHCARE

| | |
|--|---|
| Biodiversity Systemic Risks | Systemic risks arise from the potential collapse of an entire system, rather than from the failure of individual elements. They are characterized by tipping points that can combine and result in large-scale failures, with cascading interactions of physical and transitional risks (through contagion) and where systems are unable to return to equilibrium after a shock, with one loss triggering others in a chain reaction. |
|--|---|